[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369608-105":59,"doc-detail-369608-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-analysis-reveals-cldn9-is-a-new-biomarker-in-human-cancers-and-immunotherapeutic-target-for-glioblastoma-multiforme","Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme","","Claudin-9 (CLDN9) supports tight junctions and epithelial cell adhesion, yet its roles across cancers have been insufficiently investigated. This study performs a pan-cancer analysis of CLDN9 using omics data, evaluates CLDN9 expression in glioblastoma multiforme (GBM) tissues by immunohistochemistry, and tests effects on tumor growth using a subcutaneous GBM animal model. Transwell assays measure GBM migration and invasion. Results show cancer-type and subtype differences in CLDN9 expression, links to prognosis, and negative correlations with activated CD8 T cells, dendritic cell subsets, and type 1 helper cells, while CLDN9 overexpression reduces GBM migratory and invasive abilities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-analysis-reveals-cldn9-is-a-new-biomarker-in-human-cancers-and-immunotherapeutic-target-for-glioblastoma-multiforme/369608/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-analysis-reveals-cldn9-is-a-new-biomarker-in-human-cancers-and-immunotherapeutic-target-for-glioblastoma-multiforme/369608.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus of the study?","Question",{"text":112,"@type":113},"The study investigates whether CLDN9 can serve as a new biomarker and immunotherapeutic target across human cancers, with emphasis on glioblastoma multiforme (GBM).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers assess CLDN9 in GBM?",{"text":117,"@type":113},"They analyzed CLDN9 across cancer types using omics data and measured its expression in GBM tissues using immunohistochemistry (IHC).",{"name":119,"@type":110,"acceptedAnswer":120},"What functional effects did CLDN9 show in GBM models?",{"text":121,"@type":113},"CLDN9 overexpression reduced the migratory and invasive capabilities of GBM cells, and clinical correlations linked CLDN9 with immune-related factors in GBM.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369608,1790253114,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Zhu et al. Cancer Cell International (2025) 25:216 Cancer Cell International  \n[https://doi.org/10.1186/s12935-025-03852-5](https://doi.org/10.1186/s12935-025-03852-5)  \nRESEARCH Open Access  \nComprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme  \nYuanyuan Zhu 1,3,4, Ning Li 1,3 and Fang Peng 1,2,4*  \nAbstract  \nBackground Claudin-9 (CLDN9) plays a pivotal role in forming tight junctions and adhesion among epithelial cells. Despite its importance, comprehensive investigations into the role of CLDN9 in various cancers have been lacking. Methods We conducted a thorough analysis of CLDN9 across multiple cancer types using omics data and assessed its expression in glioblastoma multiforme (GBM) tissues via immunohistochemistry. To explore the impact of CLDN9 on tumor growth, we employed a subcutaneous GBM animal model. Furthermore, we utilized transwell experiments to evaluate cell migration and invasion capabilities.  \nResults Our findings reveal significant variations in CLDN9 expression across different cancers and among molecular and immune subtypes. CLDN9 demonstrates impressive predictive accuracy for certain cancer types and shows strong associations with cancer prognosis. IHC confirmed downregulated CLDN9 expression in GBM tissues, and its expression correlated with clinicopathological parameters of GBM patients. Specifically, in GBM, CLDN9 expression negatively correlated with activated CD8 T cells, activated dendritic cells, plasmacytoid dendritic cells, and type 1 helper cells. Moreover, we observed associations between CLDN9 expression and immunostimulators, immunoinhibitors, and major histocompatibility complex molecules. In vitro experiments indicated that CLDN9 overexpression reduced the migratory and invasive capabilities of GBM cells.  \nConclusions Overall, our study provides valuable insights into the role of CLDN9 in various tumors and lays a foundation for more precise and individualized immunotherapy approaches for GBM in the future.  \nKeywords CLDN9, Pan-cancer, GBM, Immunotherapeutic target  \n*Correspondence:  \nFang Peng  \n[pengfang@csu.edu.cn](pengfang@csu.edu.cn)  \n1Department of Blood Transfusion, Xiangya Hospital, Clinical Transfusion Research Center, Central South University, Changsha,  \nHunan Province 410008, China  \n2NHC Key Laboratory of Cancer Proteomics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province 410008, China  \n3Department of Clinical Laboratory, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China  \n4National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nZhu et al. Cancer Cell International (2025) 25:216  \nIntroduction  \nGlobally, cancer is one of primary cause of mortality and significantly impedes t","cbCaifauj5SL87cv","https://ap.wps.com/l/cbCaifauj5SL87cv","pdf",12675162,18,"English","# Introduction\n## Background and rationale\n# Methods\n## Multi-cancer CLDN9 analysis using omics data\n## GBM expression assessment and functional assays\n# Results\n## Pan-cancer expression variation and prognostic value\n## GBM correlations with immune features\n## In vitro functional effects on migration and invasion\n# Conclusions","[{\"question\":\"What is the main focus of the study?\",\"answer\":\"The study investigates whether CLDN9 can serve as a new biomarker and immunotherapeutic target across human cancers, with emphasis on glioblastoma multiforme (GBM).\"},{\"question\":\"How did the researchers assess CLDN9 in GBM?\",\"answer\":\"They analyzed CLDN9 across cancer types using omics data and measured its expression in GBM tissues using immunohistochemistry (IHC).\"},{\"question\":\"What functional effects did CLDN9 show in GBM models?\",\"answer\":\"CLDN9 overexpression reduced the migratory and invasive capabilities of GBM cells, and clinical correlations linked CLDN9 with immune-related factors in GBM.\"}]","Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme | PDF",1790183670,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4df6905301198b92303a55927bc64148.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cf3c2f8855595e457bb23545eeae4d3.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4c92d0bbfcd03ae426c9038a4897b35.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d3f6a9453a58e0bac8bd648dbd6568c.webp",980,1306]